These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 1939647

  • 1. Systemic lysis protects against the effects of platelet activation during coronary thrombolysis.
    Fitzgerald DJ, Hanson M, FitzGerald GA.
    J Clin Invest; 1991 Nov; 88(5):1589-95. PubMed ID: 1939647
    [Abstract] [Full Text] [Related]

  • 2. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion.
    Haskel EJ, Prager NA, Sobel BE, Abendschein DR.
    Circulation; 1991 Mar; 83(3):1048-56. PubMed ID: 1900222
    [Abstract] [Full Text] [Related]

  • 3. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.
    Przyklenk K, Kloner RA.
    Cardiovasc Res; 1993 Jun; 27(6):925-34. PubMed ID: 8221780
    [Abstract] [Full Text] [Related]

  • 4. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
    Ramjit DR, Lynch JJ, Sitko GR, Mellott MJ, Holahan MA, Stabilito II, Stranieri MT, Zhang G, Lynch RJ, Manno PD.
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
    [Abstract] [Full Text] [Related]

  • 5. Increased thromboxane biosynthesis during coronary thrombolysis. Evidence that platelet activation and thromboxane A2 modulate the response to tissue-type plasminogen activator in vivo.
    Fitzgerald DJ, Wright F, FitzGerald GA.
    Circ Res; 1989 Jul; 65(1):83-94. PubMed ID: 2500270
    [Abstract] [Full Text] [Related]

  • 6. Effects of heparin, aspirin and a synthetic platelet glycoprotein IIb-IIIa receptor antagonist (Ro 43-5054) on coronary artery reperfusion and reocclusion after thrombolysis with tissue-type plasminogen activator in the dog.
    Roux SP, Tschopp TB, Kuhn H, Steiner B, Hadváry P.
    J Pharmacol Exp Ther; 1993 Jan; 264(1):501-8. PubMed ID: 8423548
    [Abstract] [Full Text] [Related]

  • 7. Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.
    Nicolini FA, Nichols WW, Saldeen TG, Mehta JL.
    Cardiovasc Res; 1991 Apr; 25(4):283-9. PubMed ID: 1909212
    [Abstract] [Full Text] [Related]

  • 8. Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs.
    Yasuda T, Gold HK, Fallon JT, Leinbach RC, Guerrero JL, Scudder LE, Kanke M, Shealy D, Ross MJ, Collen D, Coller BS.
    J Clin Invest; 1988 Apr; 81(4):1284-91. PubMed ID: 2832448
    [Abstract] [Full Text] [Related]

  • 9. Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis.
    Ziskind AA, Gold HK, Yasuda T, Kanke M, Guerrero JL, Fallon JT, Saito T, Collen D.
    Circulation; 1989 Feb; 79(2):393-9. PubMed ID: 2492455
    [Abstract] [Full Text] [Related]

  • 10. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. I. Adjunctive therapy with monoclonal antibody 7E3 F(ab')2 fragment.
    Rote WE, Mu DX, Bates ER, Nedelman MA, Lucchesi BR.
    J Cardiovasc Pharmacol; 1994 Feb; 23(2):194-202. PubMed ID: 7511747
    [Abstract] [Full Text] [Related]

  • 11. Thrombolysis with recombinant human single-chain urokinase-type plasminogen activator (rscu-PA): dose-response in dogs with coronary artery thrombosis.
    Van de Werf F, Jang IK, Collen D.
    J Cardiovasc Pharmacol; 1987 Jan; 9(1):91-3. PubMed ID: 2434801
    [Abstract] [Full Text] [Related]

  • 12. Recombinant single-chain urokinase-type plasminogen activator (rscu-PA) induces thrombolysis and systemic fibrinolysis in a canine model of coronary artery thrombosis.
    Söhngen W, Mickelson JK, Simpson PJ, Lucchesi BR.
    Thromb Res; 1988 Jul 01; 51(1):63-74. PubMed ID: 3137691
    [Abstract] [Full Text] [Related]

  • 13. Comparative studies of thrombolysis with single-chain and two-chain recombinant tissue-type plasminogen activators in canine coronary thrombosis.
    Yokoyama M, Ichikawa Y, Yatani A, Matsui K, Nakahara H, Kaneko M, Sakurama T, Ueshima S, Matsuo O.
    J Cardiovasc Pharmacol; 1996 Oct 01; 28(4):571-5. PubMed ID: 8891884
    [Abstract] [Full Text] [Related]

  • 14. Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody.
    Yasuda T, Gold HK, Leinbach RC, Saito T, Guerrero JL, Jang IK, Holt R, Fallon JT, Collen D.
    J Am Coll Cardiol; 1990 Dec 01; 16(7):1728-35. PubMed ID: 2123910
    [Abstract] [Full Text] [Related]

  • 15. Antiplatelet antibody [7E3 F(ab')2] prevents rethrombosis after recombinant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine model.
    Mickelson JK, Simpson PJ, Cronin M, Homeister JW, Laywell E, Kitzen J, Lucchesi BR.
    Circulation; 1990 Feb 01; 81(2):617-27. PubMed ID: 2105175
    [Abstract] [Full Text] [Related]

  • 16. Functional relevance of the expression of ligand-induced binding sites in the response to platelet GP IIb/IIIa antagonists in vivo.
    Murphy NP, Pratico D, Fitzgerald DJ.
    J Pharmacol Exp Ther; 1998 Aug 01; 286(2):945-51. PubMed ID: 9694954
    [Abstract] [Full Text] [Related]

  • 17. Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
    Yao SK, Ober JC, Ferguson JJ, Anderson HV, Maraganore J, Buja LM, Willerson JT.
    Circulation; 1992 Dec 01; 86(6):1993-9. PubMed ID: 1451271
    [Abstract] [Full Text] [Related]

  • 18. Absence of potentiation with murine antiplatelet GPIIb/IIIa antibody of thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) in a canine venous thrombosis model.
    Spriggs D, Gold HK, Hashimoto Y, Van Houtte E, Vermylen J, Collen D.
    Thromb Haemost; 1989 Feb 28; 61(1):93-6. PubMed ID: 2501892
    [Abstract] [Full Text] [Related]

  • 19. Prostacyclin analogue iloprost decreases thrombolytic potential of tissue-type plasminogen activator in canine coronary thrombosis.
    Nicolini FA, Mehta JL, Nichols WW, Saldeen TG, Grant M.
    Circulation; 1990 Mar 28; 81(3):1115-22. PubMed ID: 1689620
    [Abstract] [Full Text] [Related]

  • 20. Comparison of intravenous bolus injection or continuous infusion of recombinant single chain urokinase-type plasminogen activator (saruplase) for thrombolysis. A canine model of combined coronary arterial and femoral venous thrombosis.
    Rapold HJ, Wu ZM, Stassen T, Van de Werf F, Collen D.
    Blood; 1990 Oct 15; 76(8):1558-63. PubMed ID: 2119830
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.